Article Text

Download PDFPDF
PTU-082 Responders to haemopoietic stem cell transplantation for crohn’s disease
  1. C Hawkey1,
  2. M Allez2,
  3. M Clark1,
  4. M Labopin3,
  5. J Lindsay4,
  6. E Ricart5,
  7. G Rogler6,
  8. J Satsangi7,
  9. P Kaye8,
  10. C Sharratt8,
  11. D Farge9
  12. Presentation on behalf of the ASTIC Trialists
  1. 1Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK
  2. 2Department of Gastroenterology, APHP Hopital Saint Louis
  3. 3CEREST-TC/EBMT Paris Study Office, Hopital Saint-Antoine, Paris, France
  4. 4Centre for Digestive Diseases, Barts and the London School of Medicine and Dentistry, London, UK
  5. 5Gastroenterology Department, Hospital Clinic, Barcelona, Spain
  6. 7Gastro-Intestinal Unit, University of Edinburgh, Edinburgh
  7. 8Nottigham Digestive Diseases Centre, University of Nottingham, Nottingham, UK
  8. 6Division of Gastroenterology and Hepatology, University of Zurich, Zurich, Switzerland
  9. 9Internal Medicine and Vascular Disease Unit, APHP Hopital Saint Louis, Paris, France


Introduction We recently reported that about one third of patients with Crohn’s disease experience prolonged regression of ileocolonic disease following haemopoietic stem cell transplantation (HSCT). Here we compare the characteristics of responders and non-responders.

Method Patients with impaired quality-of-life from active Crohn’s disease not amenable to surgery despite treatment with at least 3 immunosuppressive agents all underwent stem cell mobilisation before randomisation to immuno-ablation followed by unselected cyclophosphamide-based conditioning and HSCT after one month (Early HRCT) or one-year (Delayed HS CT). Patients in whom all endoscopic evidence of Crohn’s disease disappeared (SES-CD score of zero) were classified as Responders. Supporting histology was available in 17 of them.

Results Forty four patients with ileocolonic involvement underwent mobilisation before randomisation to Early or Delayed HSCT. Of 38 patients that could be classified 14 were Responders. Ten had SES-CD of zero after 1 year, (maintained in the second in 3 of 4 with available data) and 4 achieved responder status in year 2. Four of 6 followed to 4 years remain free of Crohn’s disease vs 1 of 15 non-responders. Responders were significantly more likely to have histologically normal segments post HSCT (Table 1)

Abstract PTU-082 Table 1

A Responder status tended to be more likely with no family history (39% vs 20%), in non-smokers (54% vs 30%), with early-onset of disease (Montreal A1, 46% vs 32%)) and with more than 10 year history (46% vs 17%); those with pure colonic involvement (L2) were less likely to respond than those with ileal involvement (L1, L3, 14% vs 43%) but these fell short of statistical significance on univariate analysis.

Conclusion A group of patients can be identified who have a substantial and long lasting regression of Crohn’s disease following HSCT. Endoscopic response following HSCT is associated with regression of histological evidence of Crohn’s disease.

Disclosure of interest None Declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.